DIASTROKE
Stroke
Development/CommercialActive
Key Facts
About Diagenics
Diagenics is a diagnostics company leveraging a proprietary biomarker platform to create rapid tests for emergency and critical care settings. Its product portfolio targets large markets in gynecology (preeclampsia), neurology (stroke), and cardiology (heart attack), with an additional commercial line in virology (COVID-19 antigen tests). Founded in 2005 and headquartered in Luxembourg with operational offices in Germany, the company positions itself as a pioneer in improving diagnostic speed and accuracy to influence patient outcomes.
View full company profileTherapeutic Areas
Other Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| NOX4 Inhibitor Platform | Glucox Biotech | Research |
| LG3 | Stream Biomedical | Pre-clinical |
| Patient Transport Optimization | Zeto | Research |
| NA-911 | Biomed | Phase 2A |
| APOSEC | Aposcience | Pre-clinical |
| NXL-001 | NeuExcell Therapeutics | Phase 1 |
| Precision Neuromodulation for Stroke Recovery | Panaxium | Pre-clinical |
| Autologous Wnt-activated ADSC Therapy | Regeneration Biomedical | Pre-clinical |
| NaviFUS Neuromodulation for Stroke Rehabilitation | NaviFUS | Phase 1 |
| Banked Cord Blood Stem Cells | Cryo-Cell | Clinical Trials |